Last reviewed · How we verify
TNX-832
At a glance
| Generic name | TNX-832 |
|---|---|
| Also known as | ALT-836, Sunol cH36 |
| Sponsor | Altor BioScience |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome (PHASE1)
- Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TNX-832 CI brief — competitive landscape report
- TNX-832 updates RSS · CI watch RSS
- Altor BioScience portfolio CI